Anti-proinflammatory effects of sirolimus on human islet preparations

Transplantation. 2008 Jul 15;86(1):46-53. doi: 10.1097/TP.0b013e31817c79c0.

Abstract

Background: Sirolimus plays a critical role in facilitating steroid-free immunosuppression, in conjunction with low dose tacrolimus, in current islet transplantation. Although several studies have investigated the effects of sirolimus on islet cells, conflicting results have been reported. In this study, we assessed the effects of sirolimus supplementation in culture media on human islet preparations, focusing on the anti-proinflammatory aspects.

Methods: Human islet preparations were divided into four groups: pure (purity >90%) sirolimus (30 ng/mL); pure control (0 ng/mL); impure (purity 40%-60%) sirolimus; and impure control. All groups were cultured for 3 days and assessed regarding glucose stimulated insulin release, fractional beta-cell viability, beta-cell, and macrophage content. Cytokine and chemokine production from islet preparations and sorted pancreatic ductal cells were also examined.

Results: Stimulated insulin release in the impure sirolimus group was significantly increased (P=0.024), as previously reported. Although fractional beta-cell viability showed no significant differences, beta-cell survival during culture significantly increased in impure sirolimus group when compared with the impure control group (P=0.015). Tumor necrosis factor-alpha, interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-1beta production from the impure sirolimus group significantly decreased (P<0.05). Furthermore, tumor necrosis factor-alpha and macrophage inflammatory protein-1beta production from sorted ductal cells significantly decreased in the sirolimus group (P<0.05). The number of macrophages contained in islet preparations significantly decreased in the impure sirolimus group when compared with the impure control group (P<0.05).

Conclusions: Sirolimus improved not only stimulated insulin release, but also beta-cell survival during culture. The antiinflammatory effects of sirolimus also appear beneficial to islet cells in culture and may be a useful strategy in improving islet transplantation outcomes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Cell Survival
  • Chemokine CCL2 / metabolism
  • Chemokine CCL4 / metabolism
  • Glucose / metabolism
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Inflammation Mediators / metabolism*
  • Insulin / metabolism
  • Insulin-Secreting Cells / drug effects
  • Insulin-Secreting Cells / metabolism
  • Interleukin-1beta / metabolism
  • Islets of Langerhans / drug effects*
  • Islets of Langerhans / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Pancreatic Ducts / drug effects
  • Pancreatic Ducts / metabolism
  • Sirolimus / pharmacology*
  • Time Factors
  • Tissue Culture Techniques
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Inflammatory Agents
  • CCL2 protein, human
  • CCL4 protein, human
  • Chemokine CCL2
  • Chemokine CCL4
  • Immunosuppressive Agents
  • Inflammation Mediators
  • Insulin
  • Interleukin-1beta
  • Tumor Necrosis Factor-alpha
  • Glucose
  • Sirolimus